ADAM9 and melanoma: Several studies have found that ADAM9 is overexpressed in solid tumors, including gastric cancer (GC), prostate cancer (PCa), liver cancer, melanoma, pancreatic ductal adenocarcinoma, breast cancer (BC), glioma, and lung cancer, providing a new target for the treatment of tumors [23–29].